Accrol Share Discussion Threads

[arbus5000] 16/12/2020 08:28

well it was more than that when it was half the company.

I will keep ahold of mine.

[leadersoffice] 16/12/2020 08:18

Bought in. This has £1 all over it within weeks / 2 months

[davidosh] 15/12/2020 10:58

There is a presentation with Q&A today at 2pm

Accrol Group, one of the UK's leading independent tissue converters, is pleased to announce that following the successful acquisition of Leicester Tissue Company ("LTC") in November 2020, the Group's CEO senior management team is hosting a presentation to provide retail investors with background on Accrol, the Board's strategy and ambitions and the rationale for the acquisition of LTC.

The webinar will take place at 2.00pm today, 15 December 2020, via Zoom.

If you would like to join the webinar, please email [e-mail], who will provide login details.

[stevieweebie2] 14/12/2020 11:12

I understand its a Midas tip in Sundays Mail thats rocked the boat a little this morning.
nice all the same.

[this_is_me] 14/12/2020 09:02

The share price has been on an upward trend for two years. Today's rise is just a continuation of that trend which has seen the share price just about triple in that time leaving me very happy. Plenty more to come in the next two years.

[stevieweebie2] 14/12/2020 08:28

thats a nice big gap to fill.

[stevieweebie2] 13/12/2020 16:40

Arbus TT is in very high demand at the moment, UK mills are fully stretched making orders, it's the AFH sector that's not, with no one travelling these mills are very quite and looking to take any orders for Consumer business that they can.

[arbus5000] 13/12/2020 15:15

Cool - I would imagine that there's a lull in toilet paper demand at the moment. I have a spare room full of cardboard boxes (recent have house move) and am at a bit of a loss on what to do with them

[stevieweebie2] 13/12/2020 14:53

Arbus, yes they Definitely need a PM and this will be high on the agenda for sure

[stevieweebie2] 13/12/2020 14:52

Mr all 4 lines are now in use, they are flying down in Leicester and have been for the last 2 weeks

[arbus5000] 13/12/2020 14:03

They need to get a pulping /recycling facility

[mfhmfh] 13/12/2020 13:54

ACRL had 8 tissue lines at maximum capacity. The company they have recently acquired has 4 tissue lines bit only 2 being used fully. When ACRL have the other 2 lines being used they will increase their capacity by 50% and have cost savings.

All IMHO.

[simon gordon] 13/12/2020 07:51

Came across ACRL via this Gervais Williams interview - starts 40.45:

Vox Markets - 24/11/20

[mfhmfh] 13/12/2020 01:21

Good to see they use 100% renewable energy and products are recyclable.

[philanderer] 13/12/2020 00:39

MIDAS SHARE TIPS: Don't stockpile toilet rolls - buy shares in them through Lancashire-based Accrol Group instead!

[davidosh] 10/12/2020 01:08

Just to mention that the Xmas special MelloMonday BASH may feature Accrol on the 14th December and I think shareholders and potential investors will appreciate the analysis. There is also an interview with Keith Ashworth Lord who is a highly respected fund manager and well worth listening to.

The Mello Monday event starts at 6pm
The full programme is available on the website. In the MelloBASH... The analysts, fund manager and well known investors on the panel will give their honest verdicts on whether four/five companies are a Buy Avoid Sell or Hold at this current juncture in the markets.



All investors welcome and if you use the code MMTADVFN50 you will get a half price ticket. Great investor content and entertainment. We had nearly 400 investors attend last month so these are very popular.

[geraldus] 09/12/2020 12:03

Large volume today.

[arbus5000] 09/12/2020 11:53

Well they did try to hedge against that effect a few years ago but they turned into losses :/

[geraldus] 09/12/2020 11:29

Looking at these but wary of the effect no deal Brexit .Sterling's weakness, import cost of raw material and port problems.Apart from that DS Smith director on BBC's Wake Up To Money was wary of paper/pulp price increases with the backlash against plastic packaging and online deliveries etc.Will watch for any weakness and Brexit situation.Market holding up well considering

[arbus5000] 02/12/2020 07:32

LTC is a great buy for Accrol

[davebowler] 23/11/2020 09:34

Zeus;
Transformational deal
We believe Accrol’s acquisition of LTC represents a transformational transaction which the potential to consolidate the Group’s leading position in the private label tissue market to c.30% share. On completion of the deal, the Group’s combined customer base will be stronger and broader with a step change in capacity to further accelerate its already impressive growth which continues to outpace the market. We estimate the acquisition to be 14.2% EPS enhancing in FY22E the first full year of ownership. The core Accrol business continues to trade solidly, driving an additional upgrade to our underlying numbers today. We believe Accrol’s established platform can deliver an market capitalisation of £400m+ over the medium term.

§ Acquisition overview: Accrol announced the acquisition of Leicester Tissue Company (LTC) on 2nd November, supplemented by a primary placing to raise £38.5m and an open offer raising £4.1m. The enlarged group will have c.£220m of combined revenue capacity, encompassing 12 tissue and 2 facial converting lines and c390 employees.

§ Key benefits: LTC is an established and well invested tissue converter with an impressive financial track record (70% revenue CAGR 2017-19), which we believe speaks for itself. LTC brings four high quality tissue conversion lines all under six years old to the Group, taking combined revenue capacity to c.£220m and enabling Accrol to defer £5.0m of capex spend from FY21 into FY22. The acquisition of LTC takes the Group’s private label market share from c26% pre acquisition to c30% post acquisition. We believe Accrol has paid less than 5x LTC’s FY22E EBITDA (post £1.0m anticipated synergies), which represents an attractive price for a strategically important transaction.

§ Forecasts: Our revised forecasts include an upgrade to the underlying Accrol business which has traded solidly in recent months. The acquisition should be c.14.2% EPS enhancing to our FY22E EPS forecast in the first full year of ownership on what we believe are conservative assumptions. This equates to less than 5x LTC’s 12m forward EBITDA which represents an attractive price for a strategically important transaction in our view. Cost synergies of £1.0m have been identified, which we believe is conservative, with no revenue synergies currently assumed throughout our forecast period.

§ Investment view: In our view Accrol deserves to trade at least in line, if not at a premium to its peers given its solid growth momentum. A rerating of the shares to 16x-18x FY22E PE over the next 12 months implies a share price of 69-78p. Ultimately we believe Accrol should emerge as a £35m-£40m EBITDA business (£22.5m-£30.0m previously assumed) with minimal debt and above average growth in the ever-expanding discount sector, which we believe could equate to an equity value of c.£400m (c.122p per share) over the medium term.

[red army] 19/11/2020 15:51

Added a few times to my holding as chart suggesting time to rise.

[mfhmfh] 19/11/2020 15:35

39,904 shares bought today at 52p

[mfhmfh] 04/11/2020 17:33

50k buy at 50p.